144564-14-7

Basic information

• Product Name: (4R,5S)-1-tert-butyloxycarbonyl-5-((tert-butyldiphenylsilyl)oxymethyl)-4-vinylpyrrolidin-2-one
• Synonyms: (4R,5S)-1-tert-butyloxycarbonyl-5-((tert-butyldiphenylsilyl)oxymethyl)-4-vinylpyrrolidin-2-one
• CAS NO: 144564-14-7
• Molecular Weight: 479.692
• Mol File: 144564-14-7.mol

Chemical Properties

• CAS DataBase Reference: (4R,5S)-1-tert-butyloxycarbonyl-5-((tert-butyldiphenylsilyl)oxymethyl)-4-vinylpyrrolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4R,5S)-1-tert-butyloxycarbonyl-5-((tert-butyldiphenylsilyl)oxymethyl)-4-vinylpyrrolidin-2-one(144564-14-7)
• EPA Substance Registry System: (4R,5S)-1-tert-butyloxycarbonyl-5-((tert-butyldiphenylsilyl)oxymethyl)-4-vinylpyrrolidin-2-one(144564-14-7)

Safety Data

• Hazardous Substances Data: 144564-14-7(Hazardous Substances Data)

Upstream product

• 17342-08-4 (S)-Pyroglutaminol 
• 132974-83-5 (5S)-5-[[(tert-butyldiphenylsilyl)oxy]methyl]pyrrolidin-2-one 
• 1112-56-7 tetravinyltin (IV) 
• 138871-58-6 (S)-2-(tert-butyl-diphenyl-silanyloxymethyl)-5-oxo-2,5-dihydro-pyrrole-1-carboxylic acid tert-butyl ester 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 98-79-3 L-Pyroglutamic acid 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 919349-69-2 (S)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-2-oxo-3-phenylselanyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 138629-30-8 (S)-tert-butyl 2-((tert-butyldiphenylsilyloxy)methyl)-5-oxopyrrolidine-1-carboxylate 
• 1826-67-1 vinyl magnesium bromide 

Downstream Products

• 888949-16-4 (5S)-2-methyl-5-[(1S)-1-tert-butoxycarbonylamino-2-tert-butyldiphenylsilanyloxyethyl]-3-oxo-2,3,4,5-tetrahydropyridazine 
• 691407-26-8 (4S,5S)-N-tert-butoxycarbonyl-5-tert-butyldiphenylsilyloxymethyl-2-oxopyrrolidine-4-carbaldehyde 

Relevant articles and documents

STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THE PHARMACEUTICAL USE THEREOF

The invention relates to compounds of general formula (I), which can be used particularly as structural mimetics of proline-rich peptides and are therefore capable of binding PRM binding domains (proline-rich motif binding domains) of proteins. The invention also relates to the use of said compounds as pharmaceutical active agents and the use of these pharmaceutical active agents for treating bacterial diseases, neurodegenerative diseases and tumours.

Addressing protein-protein interactions with small molecules: A pro-pro dipeptide mimic with a PPII helix conformation as a module for the synthesis of PRD-binding ligands

X marks the spot: The synthetic tricyclic amino acid X (see structure; C gray, H cyan, N blue, O red, double bond yellow) can be incorporated, without loss of binding ability, as a Pro-Pro substitute into two peptides that bind to the proline-rich motif-recognizing domains Fyn-SH3. The dipeptide analogue X, which is locked in a polyproline type II helix conformation, is created by stereoselective introduction of a vinylidene bridge into a diproline unit.

Synthesis of Homochiral R-Baclofen from S-Glutamic Acid

A streoselective synthesis of R-Baclofen is presented starting from S-pyroglutamic acid derivative 3.The key steps are the 1,4-conjugate addition of Grignard cuprate (p-ClPh)2CuMgCl to 3 and Barton-Decarboxylation of 6e to 7e.